Key statistics dashboard for Phio Pharmaceuticals Corp. (PHIO). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
Stock Data
| Price | $1.00 |
| Market Cap | $12M |
| Enterprise Value | -$1.4M |
| Beta | 0.81 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.76 |
| Price / Book | 0.94 |
| P/S | 0.00 |
| EV/EBITDA | 0.11 |
| EV/Sales | 0.00 |
| EV/FCF | 0.11 |
| P/FCF | -0.97 |
| Earnings Yield | -111.18% |
| FCF Yield | -105.19% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -87.41% |
| Return on Assets | -90.19% |
| Return on Invested Capital | -100.51% |
| Return on Capital Employed | -100.51% |
Financial Health
| Current Ratio | 15.87 |
| Quick Ratio | 15.87 |
| Cash Ratio | 14.42 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Net Debt / EBITDA | 1.00 |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -7.53 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 1.08 |
| Cash per share | 1.12 |
| FCF per share | -1.05 |
| Tangible Book Value per share | 1.08 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 2 |
| Avg rating (1-5) | 1.00 |
Related companies: ACXP · APRE · APVO · BCDA · CELZ · GLTO · INAB
Explore sector: Healthcare · Biotechnology
More sections of PHIO: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks